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Building on Breakthroughs
HIV/AIDS poses one of the world’s most serious challenges to public health and poverty reduction.
Dear Friends and Colleagues,
The HIV prevention community has had many reasons to celebrate over the past year. Several pivotal studies
have demonstrated that antiretroviral (ARV)-based prevention, whether in the form of vaginal microbicides or
once-daily oral tablets, is a safe and effective way to significantly decrease HIV infection. After decades of
persistent research—thanks to the dedication of scientists and study volunteers around the world—there is now
proof-of-concept for a technology that has the potential to save millions of lives.
For microbicides, the path forward is clear. Several microbicide studies are now underway to confirm tenofovir
gel’s ability to prevent HIV infection in women. Other planned studies will explore new, longer-acting products
that could further improve adherence and effectiveness. In the coming year, IPM, with its partner, the US National
Institutes of Health-funded Microbicide Trials Network, will advance a long-acting ARV-based microbicide ring
into a Phase III licensure program, including expanded safety studies. The ring could provide sustained protection
against HIV for a month at a time or longer.
Developing and delivering successful HIV-prevention products requires strong science and a robust pipeline of
different prevention options—along with sufficient financial resources to deliver on the promise of ARV-based
technologies for those who urgently need them.
We are deeply grateful to our donors, Board of Directors and scientific advisors for their long-standing support for
HIV prevention. We also want to acknowledge the hard work of the IPM staff and thank our former Board Chair,
Dr. Alex Coutinho, for his outstanding leadership during a year of such transformational change in the field.
This past year’s success has energized scientists and activists who have been pursuing new prevention methods
since HIV was first identified 30 years ago. It is up to all of us to work together to make this dream a reality.

Dr. Zeda F. Rosenberg							
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The HIV/AIDS epidemic not only exacts an especially high price from the world’s most vulnerable societies, it also has a
higher impact on women due to a mix of biology and social realities. In sub-Saharan Africa, young women ages 15-24
are at least twice as likely — and as much as five times as likely — as young men to be HIV positive, yet women often
lack effective tools they can use to prevent infection. This is where microbicides can play a vital role.

Microbicides: An Important Part of the
Solution for Women
Microbicides promise to address a central gap in
current HIV prevention strategies by offering practical
methods women could use to protect themselves from
infection during sex with a male partner, such as a
monthly vaginal ring or a gel used daily or around the
time of sex.
These products are based on the same types of
antiretroviral (ARV) drugs that have been used successfully for years to treat
HIV/AIDS and to
prevent motherto-child
transmission.

Proof-of-Concept for ARV-based Prevention
The past year was a watershed in HIV prevention
science: A landmark clinical trial called CAPRISA 004
established “proof-of-concept” for microbicides when it
showed that a microbicide gel containing the ARV
tenofovir provided protection for women against HIV
when used around the time of sex.
Additional milestone studies — iPrEx in 2010 and
others since then (HPTN 052, Partners PrEP, TDF2) —
have shown that ARVs, when taken orally for either
treatment or as pre-exposure prophylaxis (PrEP), can
significantly reduce the risk of HIV infection in women
and men during sex.
Taken together, these findings represent the power of
ARVs to prevent infection and revolutionize the fight
against HIV. That promise will be realized as scientists
advance recent discoveries and build on the latest
research.

Dr. Peter B. Corr
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Why a monthly microbicide ring?

The ring’s active ingredient: dapivirine

Acceptability studies reveal what women want

HIV incidence studies yield key data

Bringing the global epidemic to an end will require a
toolkit of products that match individual needs and
preferences.

Dapivirine is a potent ARV that acts as a non-nucleoside
reverse transcriptase inhibitor, or NNRTI, which works by
preventing HIV from replicating itself after the virus
enters a healthy cell.

Because even the safest and most potent microbicides
won’t work if women don’t use them, IPM takes the
preferences of women and their male partners into
account early in product development by conducting
acceptability studies.

IPM completed one HIV incidence study and began
another to measure the rate of new HIV infections in
certain communities. These studies involve thousands of
women and help determine feasible locations for future
HIV prevention efficacy trials. They also aid local and
national authorities in devising HIV prevention strategies.

Just as we know from the contraceptive field that
offering product choices greatly increases the chances
that one of them will be used, our best weapon against
the HIV epidemic will be a range of unique options — including an affordable, long-acting ARV-based microbicide ring women can use to protect themselves.
In 2010, IPM advanced the dapivirine ring, our highestpriority candidate, in clinical studies. This novel product
adapts a medical technology commonly used to deliver
hormones to women — a vaginal ring — to the fight
against HIV.

The ring offers several benefits:
Long-acting: The ring delivers the ARV drug dapivirine
over time to potentially provide protection against HIV
infection for a month or longer. Because it may offer
sustained, discreet protection and is easy to use, it
may help increase a woman’s ability to use it consistently to prevent HIV.
Combination ARVs: The ring also has the potential to
deliver long-acting combinations of ARV drugs that
target HIV at different points in its life cycle, which
may increase the level of protection.
Non-systemic protection: Products such as vaginal
rings would provide protection where it is needed
locally, with low systemic absorption, which could
minimize side effects and potentially reduce the risk
for resistance.
Contraceptive potential: Rings could combine an ARV
with a contraceptive, giving women another option to
prevent both HIV and pregnancy.
Affordability: Given its overall low cost and convenience, the microbicide ring may be a very effective
and accessible prevention option in the broader HIV
prevention toolkit.
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IPM is developing dapivirine for use in a microbicide ring
and in other formulations through a royalty-free license
granted by Tibotec Pharmaceuticals, a subsidiary of
Johnson & Johnson. It has been tested in 26 clinical
studies, all showing it to be safe and well-tolerated in
HIV-negative women.

Laying the groundwork for the ring
Last year saw the culmination of IPM’s clinical and
community engagement efforts as we laid the foundation
to advance our ring licensure program in 2012 to test the
product for efficacy and long-term safety across Africa,
in collaboration with the US National Institutes of Healthfunded Microbicide Trials Network (MTN).
In 2010, IPM oversaw 10 research studies that
engaged researchers, local health workers,
communities and study volunteers
across IPM research center partner
sites throughout Africa and Europe,
and in the United States.

Women like the ring: In an acceptability study of the
ring among 170 women at four sites in South Africa
and Tanzania which concluded in 2010, 96 percent
of women said they liked using the ring – and 100
percent of women said they would use it if proved
effective against HIV. Many women indicated interest
in discreet use, though most preferred partner
involvement. In that regard, the male partners
interviewed also expressed support for the ring.
Variety of options: An IPM market research study of
526 women in Burkina Faso, Tanzania and Zambia
revealed in 2010 that vaginal tablets, films and soft
gel capsules are also acceptable product forms to
women in Africa. This suggests that providing
multiple product options may increase the likelihood
microbicides will be used in the real world.

South Africa: One study, conducted at five sites in
South Africa, showed annual incidence rates (the
number of new infections) ranging between 4 percent
and 11 percent, with the highest rates in KwaZuluNatal. Prevalence rates (the current percentage of
people living with HIV) reach as high as 46 percent in
women between 18 and 35, with the highest numbers in the same region. These findings support
evidence that South Africa, and the KwaZulu-Natal
province specifically, has some of the highest HIV
rates worldwide.
Kenya and Zimbabwe: Another study, underway in
Suba, Kenya, and Mutare, Zimbabwe, is fully enrolled, with 600 participants. The results, expected in
2012, will provide critically needed public health data
on the HIV epidemic in these communities.

Ring safety studies to support licensure program
IPM initiated a Phase I/II safety study of the dapivirine
ring in 2010 in Kenya, Malawi, South Africa and Tanzania, with results expected in 2011. This data will further
contribute to the product’s safety profile as part
of the licensure program. This study, which
attracted global media attention, tested the
first long-acting microbicide in Africa.
Findings reported in 2010 from two additional studies in Belgium show the ring
successfully delivered dapivirine over a
month or longer, and was safe and
well-tolerated in HIV-negative women.
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PDPs: Agents of Progress
IPM is one of many nonprofit “product development partnerships”
that operate by coupling the business approach of the private sector
with the public sector’s commitment to improving global public
health and access to products. PDPs like IPM remain flexible and
efficient, while forging partnerships that leverage resources and
scientific ingenuity to develop life-saving technologies.
For example, it is hoped that IPM’s new partnership with MTN on the
dapivirine ring serves as a model for future collaboration in the field.

Gel studies progress in US and Africa
IPM also progressed three safety studies of dapivirine gel
in 2010 — two in Africa and one in the United States —
data from which will also support the ring’s safety profile,
with results expected in 2011.
“DMA” trial design: Notably, the gel studies in Africa
piloted an innovative design called “daily monitored
adherence,” or DMA, during which study participants
had daily contact with researchers either by home visits
or returning the gels daily to a local drop-off center. The
DMA strategy showed high participant retention, and
increased opportunities for counseling and follow-up.
These findings may inform future trial designs in the
field and help improve our ability to accurately measure
adherence.
Male tolerance study: IPM partnered with MTN in 2010
to plan a US-based dapivirine study to assess the
safety of dapivirine gel for men when applied once daily.
Results are expected in late 2011 and will inform the
safety package for the ring licensure program.

Partnering to advance the ring licensure program
Given the ring’s promise as a microbicide, MTN and IPM
recently expanded their partnership to help advance the
ring licensure program. This new collaboration brings
complementary scientific strengths and resources to this
important effort while creating operational efficiencies. Next
steps for the ring program include a pivotal Phase III
efficacy study that involves 3,500 healthy, HIV-negative
women, which MTN will conduct at its existing sites in
southern and eastern Africa, adding its considerable Phase
III clinical expertise to the program.
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Building on IPM’s research through 2010 showing the ring’s
good safety profile, ease-of-use and long-acting duration,
IPM will conduct a Phase II long-term safety study at its
research center partner sites in Africa. This trial will be done
in parallel with additional studies to examine the ring’s
safety in specific populations, such as adolescents, as well
as any drug interactions. Conducting parallel safety studies
may speed future regulatory approval for the ring.

Ring Manufacturing

Other products — and partnerships — in the pipeline

Partnering to build capacity

IPM focused its resources on advancing the ring in 2010,
and also worked on other promising candidates in the
pipeline as part of innovative collaborations designed to
expand HIV prevention options for women in the world’s
most at-risk regions. Highlights follow:

As IPM works to advance HIV prevention products for use in developing
countries, it also partners with research centers across
Africa to build capacities there, directly benefiting the
communities involved and helping to advance the United
Nations Millennium Development Goals. In 2010, IPM
worked with a variety of research center partners across
Africa to build medical research capabilities through
trainings and scientific meetings, strengthening infrastructure, and offering employment and professional development opportunities.

ARV-contraceptive ring: IPM began work with the
Population Council on a prototype microbicide-contraceptive ring that would deliver dapivirine and the
hormone levonorgestrel.

IPM will provide the tens of thousands of dapivirine rings
and placebo rings for the upcoming studies. In 2010, we
worked with our manufacturing partner, QPharma (Malmö,
Sweden), to keep manufacturing costs low as we added
equipment and built capacity to prepare for ring production
in 2011.

Combination ARV ring: IPM partnered with MTN to bring
a combination dapivirine-maraviroc monthly ring to
clinical trial. This first-ever study of a combination
microbicide will start in 2011 in the United States. MTN
will conduct the study and IPM, as the product developer, will act as the regulatory sponsor and provide the
rings needed for the study.

Pathways to Access

Long-acting PrEP: IPM continued its collaboration in
2010 with Tibotec Pharmaceuticals on a monthly
injectable form of PrEP based on TMC278, or rilpivirine, an ARV recently approved for oral HIV treatment.

Once the studies are complete, IPM will seek marketing
approval for the ring to make it available at the lowest
possible cost to women who urgently need new HIV
prevention tools.
Preparations for future access continued in 2010, with IPM
holding discussions with regulatory agencies in Africa,
Europe and the US as well as the World Health Organization. IPM also hosted an annual meeting in 2010 in Cape
Town, sponsored by the European Commission, that
convened regulatory and ethics representatives from
across Africa to build understanding about microbicides
and begin resolving potential challenges to access in the
future.

In addition, IPM’s engagement with major pharmaceutical partners
in the HIV prevention effort has led to six non-exclusive, royalty-free
licensing agreements for IPM to develop, manufacture and distribute
eight different ARVs as microbicides in
developing countries. These licenses, the core
of our public-private partnerships, help ensure
that any new product will be affordable and
accessible in the settings where they are
urgently needed.

Entry inhibitors: IPM has provided four licensed compounds known as entry inhibitors — which prevent HIV
from entering healthy cells — to multiple organizations
for development as single and combination microbicides under an NIH grant led by Cornell University.

Partnering to raise awareness
Raising awareness is crucial to ensuring broad support for
microbicides and access to future products. IPM’s partnerships with civil society organizations produced a wide
range of awareness-raising activities in 2010, including
parliamentary briefings in North America and Europe, a
program of microbicide advocacy events observing South
Africa’s National Women’s Day, and educational symposia
on microbicides and HIV prevention research held at medical conferences in Africa and Europe.

Other dapivirine-based products: IPM provided dapivirine to collaborators across the globe for research on
such projects as developing dapivirine-loaded
nanoparticles as a microbicide, incorporating dapivirine
into a contraceptive cervical cap device, and testing
the safety of a dapivirine vaginal film.
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Funding considerations

Donors

IPM Donors
our dapivirine licensure program by 2015. IPM has made
dramatic shifts in resource allocations due to the fiscal
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2009
Dec.31,
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Thus, in expens$8,337,020
$17,183,386
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$5,040,274
ships,
and a committed Board of
Directors and manage$95,049,685
$121,126,028
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Board of Directors

Scientific Advisory Board

IPM Executive Leadership

Peter B. Corr, PhD, Chair

Robin Shattock, PhD, Chair

Zeda F. Rosenberg, ScD

Celtic Therapeutics LLLP, United States

St. George’s, University of London, United Kingdom

Chief Executive Officer

Stefano Bertozzi, MD, PhD

Michael Chirenje, MD

Michael Goldrich, MBA

Bill & Melinda Gates Foundation, United States

University of Zimbabwe, Zimbabwe

Executive Vice President, Chief Operating and Financial Officer

Eunice Brookman-Amissah, MBChB

David R. Friend, PhD

Annalene Nel, MD, PhD

Ipas, Kenya

CONRAD, United States

Chief Medical Officer

Georgina Caswell, MA

Sharon Hillier, PhD

Brid Devlin, PhD

Global Network of People Living with HIV, South Africa

Magee-Womens Hospital, University of Pittsburgh School of
Medicine, United States

Executive Vice President, Product Development

Eveline Herfkens, MA
UN Millennium Development Goals Campaign, Switzerland

Ronald Nardi, PhD
Ruth B. Merkatz, PhD, RN, FAAN
Population Council, United States

Executive Vice President, Regulatory Affairs
and Quality Assurance

Thomas Moench, MD

Kathleen T. Ross, PhD

ReProtect, Inc., United States

Executive Vice President, Human Resources

David Kessler, JD, MD
University of California, San Francisco, United States

Maureen Lewis, PhD
World Bank, United States

Edith Nakku-Joloba, PhD
Makerere University Kampala, Uganda

Florence W. Manguyu, M.Med, MBChB
Aga Khan University Hospital; IAVI, Kenya

Derek Newall, PhD
GlaxoSmithKline, United Kingdom

Totsie Memela-Khambula, MPA
Eduloan, South Africa

Lynn Paxton, MD, MPH
US Centers for Disease Control and Prevention, United States

Anjali Nayyar, MA
Global Health Strategies, India

Deenan Pillay, MD

Albert Profy, PhD

University College London School of Life and Medical
Sciences, United Kingdom

Ironwood Pharmaceuticals, United States

Renee Ridzon, MD
Zeda F. Rosenberg, ScD

Bill & Melinda Gates Foundation, United States

IPM, United States

Doug Taylor, PhD
Anandi Yuvaraj, MSc, MPhil, PGDGC
International Community of Women Living with HIV/AIDS,
Thailand

Family Health International, United States

Jens Van Roey, MD
Tibotec BVBA, Belgium

Robin Wood, PhD
Desmond Tutu HIV Centre, South Africa
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To learn more about how to
prevent HIV in women
worldwide and help save
millions of lives, visit
www.IPMglobal.org.

IPM Headquarters

IPM South Africa

IPM Belgium

8401 Colesville Road

Main Street 121

2/3 Place du Luxembourg

Suite 200

Paarl 7646, South Africa

1050 Brussels

Silver Spring, MD 20910 USA

P.O. Box 3460

Belgium

Tel: +1-301-608-2221

Tel: +27-21-860-2300

Tel: +32 (0) 2 504 90 61

Fax: +1-301-608-2241

Fax: +27-21-860-3208/1000

Fax: +32 (0) 2 502 76 52

